A 6-Day Losing Streak Has IQVIA Stock Down 7.6%

IQVYTD+14.4%SPYYTD+7.9%XLVYTD+18.5%
Analyze IQV →

Today’s big story: Anthropic IPO: Priced For 2031, Or 2036?

Shares of IQVIA (IQV) have closed lower in each of the last 6 sessions, a cumulative decline of 7.6%. That erased about $3.5 billion from the company’s market value, which now stands at about $42.4 billion. The stock closed at $257.60 on Tuesday, November 17, 7.8% below its 52-week high of $279.36 and 64.4% above its low of $156.66.

Image from Pixabay

 
How The Streak Stacks Up Against The S&P 500

Returns for IQV and the S&P 500 over the streak and the periods around it, all ending Tuesday, November 17 and including dividends:
 

Return Period IQV S&P 500
1 Day -2.7% -1.0%
6 Days (Current Streak) -7.6% -2.7%
1 Month (21 Trading Days) -3.1% -4.5%
3 Months (63 Trading Days) 3.3% -4.5%
Year To Date 14.3% 8.3%
1 Year (252 Trading Days) 16.8% 10.3%

How The Streak Compares With The Market

Over the same 6 trading days, the S&P 500 returned -2.7% including dividends, so the slide is mostly IQVIA’s own story rather than the market’s. 13 other S&P 500 stocks are currently on losing streaks of 6 days or longer. Over the past three months the stock is up 3.3%, a window that includes the streak; over the other 57 sessions of that window it was up 11.9%.

Is The Business As Weak As The Stock?

On the fundamentals, revenue grew 8.8% over the last twelve months, against a median of 7.9% for S&P 500 Health Care stocks; its operating margin is 13.8%, versus a median of 17.4%; and the stock trades at 30.4 times trailing earnings against a median of 30.7. The selling is hard to square with the fundamentals: revenue growth above the median and a multiple below the median.

A slide like this raises an obvious follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.

A Slide Like This Is Why Diversification Exists

Watching one stock fall day after day is the clearest lesson the market teaches about single-name risk. Whether this particular decline is an opportunity or a warning, the deeper point is the same: no one name should be able to do this to your portfolio.

The Trefis High Quality (HQ) Portfolio is built on that principle: roughly 30 businesses selected for consistent cash generation, strong margins, and resilient balance sheets, sized and rebalanced with rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Study the slide; spread the risk.